Skip to content

Study · Randomized controlled trial · n = 21 · 1992

5 results

An effective regimen of intranasal salmon calcitonin in early postmenopausal bone loss.

Gennari C, Agnusdei D, Montagnani M, Gonnelli S, Civitelli R

Calcified tissue international1 Apr 1992Cited by 39 (Europe PMC)

PMID1571851 (opens in a new tab)DOI10.1007/bf00301638 (opens in a new tab)PepBankPUB-01571851
Publisher pagePubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In early postmenopausal osteoporotic women, sCT increased vertebral mineral content by 2.7 +/- 0.9%, versus a placebo decline of 2.6 +/- 0.5%.

    In plain wordsIn early postmenopausal osteoporotic women, sCT increased vertebral mineral content, while placebo reduced it at six months.

    Peptide
    Calcitonin-salmon
    Outcome
    IncreaseVertebral mineral content at 6 months
    Study

    n = 21

    Comparator
    Placebo
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    200 IU every other day · intranasal · 6 monthsAs given in this study (human).

    Measurements

    Vertebral mineral content change at 6 months
    2.7%
    sCT 200 IU every other day, +/- 0.9
    Vertebral mineral content change at 6 months
    −2.6%
    placebo, +/- 0.5

    Source sentences

    Summary
    Treatment with sCT significantly increased VMC by 2.7 +/- 0.9% at 6 months, and 3.3 +/- 0.8% at 1 year, whereas a progressive decline was observed in the placebo group (-2.6 +/- 0.5%, and -3.5 +/- 0.5% after 6 and 12 months, respectively).
    2 context sentences
    Summary · context
    we studied the effects of a 1-year course of sCT nasal spray on vertebral mineral content (VMC), assessed by dual photon densitometry, and bone turnover in 21 early postmenopausal osteoporotic women.
    Summary · context
    After baseline evaluation, patients were randomized for treatment with either sCT (200 IU every other day) or placebo.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In early postmenopausal osteoporotic women, sCT increased vertebral mineral content by 3.3 +/- 0.8%, versus a placebo decline of 3.5 +/- 0.5%.

    In plain wordsIn early postmenopausal osteoporotic women, sCT increased vertebral mineral content more than placebo at one year.

    Peptide
    Calcitonin-salmon
    Outcome
    IncreaseVertebral mineral content at 1 year
    Study

    n = 21

    Comparator
    Placebo
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    200 IU every other day · intranasal · 1 yearAs given in this study (human).

    Measurements

    Vertebral mineral content change at 1 year
    3.3%
    sCT 200 IU every other day, +/- 0.8
    Vertebral mineral content change at 1 year
    −3.5%
    placebo, +/- 0.5

    Source sentences

    Summary
    Treatment with sCT significantly increased VMC by 2.7 +/- 0.9% at 6 months, and 3.3 +/- 0.8% at 1 year, whereas a progressive decline was observed in the placebo group (-2.6 +/- 0.5%, and -3.5 +/- 0.5% after 6 and 12 months, respectively).
    3 context sentences
    Summary · context
    The differences between the two groups were significant after 1 year for VMC, BGP, and WBR (P less than 0.05, one-way analysis of variance).
    Summary · context
    we studied the effects of a 1-year course of sCT nasal spray on vertebral mineral content (VMC), assessed by dual photon densitometry, and bone turnover in 21 early postmenopausal osteoporotic women.
    Summary · context
    After baseline evaluation, patients were randomized for treatment with either sCT (200 IU every other day) or placebo.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In early postmenopausal osteoporotic women, sCT reduced BGP, with a significant difference versus placebo after 1 year (P less than 0.05).

    In plain wordsIn early postmenopausal osteoporotic women, sCT reduced the bone turnover marker BGP compared with placebo.

    Peptide
    Calcitonin-salmon
    Outcome
    DecreaseSerum bone gla protein
    Study

    n = 21

    Comparator
    Placebo
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    200 IU every other day · intranasal · 1 yearAs given in this study (human).

    Source sentences

    Summary
    The differences between the two groups were significant after 1 year for VMC, BGP, and WBR (P less than 0.05, one-way analysis of variance).
    3 context sentences
    Summary · context
    These changes were associated with a progressive and significant reduction of all parameters of bone turnover in the sCT-treated patients, whereas no changes were detected in the control group during the study period.
    Summary · context
    we studied the effects of a 1-year course of sCT nasal spray on vertebral mineral content (VMC), assessed by dual photon densitometry, and bone turnover in 21 early postmenopausal osteoporotic women.
    Summary · context
    After baseline evaluation, patients were randomized for treatment with either sCT (200 IU every other day) or placebo.
  4. 04HumanRandomized controlled trialEfficacy outcome

    In early postmenopausal osteoporotic women, sCT reduced WBR, with a significant difference versus placebo after 1 year (P less than 0.05).

    In plain wordsIn early postmenopausal osteoporotic women, sCT reduced the bone turnover measure WBR compared with placebo.

    Peptide
    Calcitonin-salmon
    Outcome
    DecreaseWhole body retention of 99mTc-MDP
    Study

    n = 21

    Comparator
    Placebo
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    200 IU every other day · intranasal · 1 yearAs given in this study (human).

    Source sentences

    Summary
    The differences between the two groups were significant after 1 year for VMC, BGP, and WBR (P less than 0.05, one-way analysis of variance).
    3 context sentences
    Summary · context
    These changes were associated with a progressive and significant reduction of all parameters of bone turnover in the sCT-treated patients, whereas no changes were detected in the control group during the study period.
    Summary · context
    we studied the effects of a 1-year course of sCT nasal spray on vertebral mineral content (VMC), assessed by dual photon densitometry, and bone turnover in 21 early postmenopausal osteoporotic women.
    Summary · context
    After baseline evaluation, patients were randomized for treatment with either sCT (200 IU every other day) or placebo.
  5. 05HumanNon-randomized trialEfficacy outcome

    In early postmenopausal osteoporotic women, sCT significantly reduced urinary HOP/Cr, while controls showed no change.

    In plain wordsIn early postmenopausal osteoporotic women, sCT reduced urinary HOP/Cr, while placebo showed no change.

    Peptide
    Calcitonin-salmon
    Outcome
    DecreaseUrinary hydroxyproline/creatinine excretion
    Study

    n = 21

    Comparator
    Placebo
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    200 IU every other day · intranasal · 1 yearAs given in this study (human).

    Source sentences

    Summary
    These changes were associated with a progressive and significant reduction of all parameters of bone turnover in the sCT-treated patients, whereas no changes were detected in the control group during the study period.
    3 context sentences
    Summary · context
    whole body retention (WBR) of 99mTc-methylene-dichloro-bisphosphonate (99mTc-MDP), serum bone gla protein (BGP), urinary hydroxyproline/creatinine excretion (HOP/Cr).
    Summary · context
    we studied the effects of a 1-year course of sCT nasal spray on vertebral mineral content (VMC), assessed by dual photon densitometry, and bone turnover in 21 early postmenopausal osteoporotic women.
    Summary · context
    After baseline evaluation, patients were randomized for treatment with either sCT (200 IU every other day) or placebo.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:35 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.